Cargando…

Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076]

BACKGROUND: Bronchiolitis is the most common cause of lower respiratory tract illness in infancy, and hospital admission rates appear to be increasing in Canada and the United States. Inhaled beta agonists offer only modest short-term improvement. Trials of racemic epinephrine have shown conflicting...

Descripción completa

Detalles Bibliográficos
Autores principales: Langley, Joanne M, Smith, Michael B, LeBlanc, John C, Joudrey, Heather, Ojah, Cecil R, Pianosi, Paul
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1142326/
https://www.ncbi.nlm.nih.gov/pubmed/15876347
http://dx.doi.org/10.1186/1471-2431-5-7
_version_ 1782124276388724736
author Langley, Joanne M
Smith, Michael B
LeBlanc, John C
Joudrey, Heather
Ojah, Cecil R
Pianosi, Paul
author_facet Langley, Joanne M
Smith, Michael B
LeBlanc, John C
Joudrey, Heather
Ojah, Cecil R
Pianosi, Paul
author_sort Langley, Joanne M
collection PubMed
description BACKGROUND: Bronchiolitis is the most common cause of lower respiratory tract illness in infancy, and hospital admission rates appear to be increasing in Canada and the United States. Inhaled beta agonists offer only modest short-term improvement. Trials of racemic epinephrine have shown conflicting results. We sought to determine if administration of racemic epinephrine during hospital stay for bronchiolitis improved respiratory distress, was safe, and shortened length of stay. METHODS: The study was a randomized, double-blind controlled trial of aerosolized racemic epinephrine compared to salbutamol every one to 4 hours in previously well children aged 6 weeks to ≤ 2 years of age hospitalized with bronchiolitis. The primary outcome was symptom improvement as measured by the Respiratory Distress Assessment Instrument (RDAI); secondary outcomes were length of stay in hospital, adverse events, and report of symptoms by structured parental telephone interview one week after discharge. RESULTS: 62 children with a mean age of 6.4 months were enrolled; 80% of children had Respiratory Syncytial Virus (RSV). Racemic epinephrine resulted in significant improvement in wheezing and the total RDAI score on day 2 and over the entire stay (p < 0.05). The mean LOS in the epinephrine arm was 2.6 days (95% CI 2, 3.2) v. 3.4 days in those in the salbutamol group (95% CI 2.6, 4.2) (p > 0.05). Adverse events were not significantly different in the two arms. At one week post-discharge, over half of parents reported that their child still had a respiratory symptom and 40% had less than normal feeding. CONCLUSION: Racemic epinephrine relieves respiratory distress in hospitalized infants with bronchiolitis and is safe but does not abbreviate hospital stay. Morbidity associated with bronchiolitis as identified by parents persists for at least one week after hospital discharge in most infants.
format Text
id pubmed-1142326
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-11423262005-06-03 Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076] Langley, Joanne M Smith, Michael B LeBlanc, John C Joudrey, Heather Ojah, Cecil R Pianosi, Paul BMC Pediatr Research Article BACKGROUND: Bronchiolitis is the most common cause of lower respiratory tract illness in infancy, and hospital admission rates appear to be increasing in Canada and the United States. Inhaled beta agonists offer only modest short-term improvement. Trials of racemic epinephrine have shown conflicting results. We sought to determine if administration of racemic epinephrine during hospital stay for bronchiolitis improved respiratory distress, was safe, and shortened length of stay. METHODS: The study was a randomized, double-blind controlled trial of aerosolized racemic epinephrine compared to salbutamol every one to 4 hours in previously well children aged 6 weeks to ≤ 2 years of age hospitalized with bronchiolitis. The primary outcome was symptom improvement as measured by the Respiratory Distress Assessment Instrument (RDAI); secondary outcomes were length of stay in hospital, adverse events, and report of symptoms by structured parental telephone interview one week after discharge. RESULTS: 62 children with a mean age of 6.4 months were enrolled; 80% of children had Respiratory Syncytial Virus (RSV). Racemic epinephrine resulted in significant improvement in wheezing and the total RDAI score on day 2 and over the entire stay (p < 0.05). The mean LOS in the epinephrine arm was 2.6 days (95% CI 2, 3.2) v. 3.4 days in those in the salbutamol group (95% CI 2.6, 4.2) (p > 0.05). Adverse events were not significantly different in the two arms. At one week post-discharge, over half of parents reported that their child still had a respiratory symptom and 40% had less than normal feeding. CONCLUSION: Racemic epinephrine relieves respiratory distress in hospitalized infants with bronchiolitis and is safe but does not abbreviate hospital stay. Morbidity associated with bronchiolitis as identified by parents persists for at least one week after hospital discharge in most infants. BioMed Central 2005-05-05 /pmc/articles/PMC1142326/ /pubmed/15876347 http://dx.doi.org/10.1186/1471-2431-5-7 Text en Copyright © 2005 Langley et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Langley, Joanne M
Smith, Michael B
LeBlanc, John C
Joudrey, Heather
Ojah, Cecil R
Pianosi, Paul
Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076]
title Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076]
title_full Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076]
title_fullStr Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076]
title_full_unstemmed Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076]
title_short Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076]
title_sort racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [isrctn46561076]
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1142326/
https://www.ncbi.nlm.nih.gov/pubmed/15876347
http://dx.doi.org/10.1186/1471-2431-5-7
work_keys_str_mv AT langleyjoannem racemicepinephrinecomparedtosalbutamolinhospitalizedyoungchildrenwithbronchiolitisarandomizedcontrolledclinicaltrialisrctn46561076
AT smithmichaelb racemicepinephrinecomparedtosalbutamolinhospitalizedyoungchildrenwithbronchiolitisarandomizedcontrolledclinicaltrialisrctn46561076
AT leblancjohnc racemicepinephrinecomparedtosalbutamolinhospitalizedyoungchildrenwithbronchiolitisarandomizedcontrolledclinicaltrialisrctn46561076
AT joudreyheather racemicepinephrinecomparedtosalbutamolinhospitalizedyoungchildrenwithbronchiolitisarandomizedcontrolledclinicaltrialisrctn46561076
AT ojahcecilr racemicepinephrinecomparedtosalbutamolinhospitalizedyoungchildrenwithbronchiolitisarandomizedcontrolledclinicaltrialisrctn46561076
AT pianosipaul racemicepinephrinecomparedtosalbutamolinhospitalizedyoungchildrenwithbronchiolitisarandomizedcontrolledclinicaltrialisrctn46561076